Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
Delayed Quote. Delayed Xetra - 12/03 11:40:39 am
40.09 EUR   -2.10%
12/01EVOTEC : Deutsche Bank sticks Neutral
MD
11/29EVOTEC : Receives a Buy rating from RBC
MD
11/29EVOTEC : Raised to Buy by Jefferies
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

German biotech Evotec seeks over $9 bln valuation in U.S. IPO

10/26/2021 | 02:41pm EST

Oct 26 (Reuters) - German biotech firm Evotec SE said on Tuesday it would seek a valuation of about $9.2 billion in its initial public offering in the United States.

The company has a market capitalization of $8.3 billion on the Frankfurt Stock Exchange, where its shares are already listed, according to Refinitiv data.

Founded in 1993, Hamburg-headquartered Evotec offers a suite of technologies that enable faster and cheaper drug discoveries by pharmaceutical companies.

The company last year received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody drugs for the prevention of severe COVID-19.

Evotec said in its filing that it would look to raise up to $575.5 million in the IPO by offering 22 million American depositary shares (ADSs) at $26.16 each. Each ADS represents one-half of an ordinary share.

BofA Securities and Morgan Stanley are the lead underwriters for the offering. (Reporting by Niket Nishant in Bengaluru; Editing by Krishna Chandra Eluri and Aditya Soni)


ę Reuters 2021
All news about EVOTEC SE
12/01EVOTEC : Deutsche Bank sticks Neutral
MD
11/29EVOTEC : Receives a Buy rating from RBC
MD
11/29EVOTEC : Raised to Buy by Jefferies
MD
11/18EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
BU
11/18EVOTEC : and EQRx announce integrated drug discovery and development partnership
PU
11/18Evotec and EQRx announce integrated drug discovery and development partnership
EQ
11/18Evotec SE and EQRx Announce Integrated Drug Discovery and Development Partnership
CI
11/16EVOTEC : announces the exercise of the Greenshoe option
PU
11/12EVOTEC : Deutsche Bank reaffirms its Neutral rating
MD
11/12Evotec SE Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe..
CI
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2021 574 M 649 M 649 M
Net income 2021 237 M 268 M 268 M
Net cash 2021 418 M 473 M 473 M
P/E ratio 2021 28,9x
Yield 2021 -
Capitalization 7 022 M 7 927 M 7 944 M
EV / Sales 2021 11,5x
EV / Sales 2022 10,3x
Nbr of Employees 4 081
Free-Float 87,6%
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | EVT | DE0005664809 | MarketScreener
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 40,09 €
Average target price 43,02 €
Spread / Average Target 7,31%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris L÷w-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE32.40%7 927
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298